We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDXX icon
51
Idexx Laboratories
IDXX
$44.1B
$11.4M 0.43%
43,614
-6,162
-12% -$1.62M
VTR icon
52
Ventas
VTR
$44.7B
$11.1M 0.42%
191,388
+50,269
+36% +$3.16M
HZNP
53
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11M 0.42%
304,664
+89,934
+42% +$2.76M
TECH icon
54
Bio-Techne
TECH
$11.2B
$11M 0.42%
200,364
+78,216
+64% +$4.1M
BAX icon
55
Baxter International
BAX
$13.8B
$10.9M 0.41%
129,983
-34,975
-21% -$2.89M
AGIO icon
56
Agios Pharmaceuticals
AGIO
$1.95B
$10.3M 0.39%
216,408
+74,191
+52% +$2.8M
IMMU
57
DELISTED
Immunomedics Inc
IMMU
$10.3M 0.39%
487,103
– –
MDCO
58
DELISTED
Medicines Co
MDCO
$10.3M 0.39%
120,670
-15,005
-11% -$1M
SBRA icon
59
Sabra Healthcare REIT
SBRA
$5.38B
$9.95M 0.38%
466,247
– –
COR icon
60
Cencora
COR
$60.7B
$9.84M 0.37%
115,723
-58,615
-34% -$5.02M
ASND icon
61
Ascendis Pharma A/S
ASND
$16.5B
$9.64M 0.36%
69,332
-7,835
-10% -$870K
ZBH icon
62
Zimmer Biomet
ZBH
$18.4B
$9.53M 0.36%
65,581
-14,317
-18% -$1.98M
CNC icon
63
Centene
CNC
$30.1B
$9.4M 0.36%
+149,526
New +$8.11M
SNY icon
64
Sanofi
SNY
$103B
$9.37M 0.35%
186,640
+100,699
+117% +$4.72M
BPMC
65
DELISTED
Blueprint Medicines
BPMC
$9.37M 0.35%
116,925
+16,009
+16% +$1.2M
ACAD icon
66
Acadia Pharmaceuticals
ACAD
$4.55B
$9.34M 0.35%
218,283
+58,136
+36% +$2.53M
MCK icon
67
McKesson
MCK
$101B
$9.31M 0.35%
67,325
-39,941
-37% -$5.65M
MRTX
68
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.13M 0.35%
70,873
-8,814
-11% -$850K
EXEL icon
69
Exelixis
EXEL
$14.1B
$9.08M 0.34%
515,125
+183,374
+55% +$3.11M
NVCR icon
70
NovoCure
NVCR
$1.77B
$9.05M 0.34%
107,438
+6,506
+6% +$525K
AMRN
71
Amarin Corp
AMRN
$298M
$8.75M 0.33%
20,406
+5,978
+41% +$2.27M
EPZM
72
DELISTED
Epizyme, Inc
EPZM
$8.69M 0.33%
353,102
-46,502
-12% -$690K
DOC
73
DELISTED
PHYSICIANS REALTY TRUST
DOC
$8.65M 0.33%
456,756
+152,848
+50% +$2.8M
BLUE
74
DELISTED
bluebird bio
BLUE
$8.4M 0.32%
7,387
-3,443
-32% -$3.74M
KYNB
75
Kyntra Bio
KYNB
$27.5M
$8.33M 0.32%
7,771
-1,555
-17% -$1.59M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.